Altitude Life Science Ventures
Venture firm that invests in early-stage life science companies and provides IP-focused strategic planning and operational support. Investment scope includes therapeutics, diagnostics, gene editing, AI/ML therapeutics, autonomous science, medical devices, drug delivery platforms and sequencing-related technologies. Emphasizes extended technical and intellectual property due diligence to support commercialization and value preservation.
Industries
Nr. of Employees
small (1-50)
Altitude Life Science Ventures
Services
Equity investments in early-stage companies across therapeutics, diagnostics, platform technologies and related commercial applications of advances in biology and chemistry.
Advisory services to design and execute multi-layered patent portfolios that track technology maturation and support commercialization and licensing.
Extended diligence including scientific, manufacturing and regulatory assessments to inform investment decisions and commercialization planning.
Equity investments in early-stage companies across therapeutics, diagnostics, platform technologies and related commercial applications of advances in biology and chemistry.
Advisory services to design and execute multi-layered patent portfolios that track technology maturation and support commercialization and licensing.
Extended diligence including scientific, manufacturing and regulatory assessments to inform investment decisions and commercialization planning.
Expertise Areas
- Venture investment for early-stage life sciences
- Intellectual property strategy and patent portfolio planning
- Technical and IP-focused due diligence
- Commercialization and regulatory planning support
Key Technologies
- Gene editing
- AI / machine learning for drug discovery
- Autonomous laboratory automation
- RNA therapeutics (e.g., RNA expression platforms, RNAi)
News & Updates
Report of six-month clinical results from a study of islet cell transplantation without immunosuppression (portfolio company news featured on firm site).
FDA approval announcement for a portfolio company treatment described on firm site.
Announcement of a research collaboration leveraging RNAi technologies (featured on firm site news).
FDA approval news for a portfolio company device highlighted on the firm site.
Report of six-month clinical results from a study of islet cell transplantation without immunosuppression (portfolio company news featured on firm site).
FDA approval announcement for a portfolio company treatment described on firm site.
Announcement of a research collaboration leveraging RNAi technologies (featured on firm site news).
FDA approval news for a portfolio company device highlighted on the firm site.